Divi's Laboratories Ltd.

NSE: DIVISLAB | BSE: 532488 | ISIN: INE361B01024 | Industry: Pharmaceuticals
| Expensive Performer
6544.5000 -84.00 (-1.27%)
NSE Jun 06, 2025 15:31 PM
Volume: 361.1K
 

6544.50
-1.27%
BOB Capital Markets Ltd.
LICI: Solid quarter; valuations overdone cut to HOLD. ALKEM: Good quarter; cut to SELL on stretched valuations. Monthly Chartbook: Fiscal consolidation to hold key. PWGR: In-line quarter, FY25 capex hiked; maintain BUY. TATACONS: Strong run continues. DIVI: Healthy margin recovery, heady valuations. TPW: Dull quarter; high valuations maintain HOLD. ESCORTS: Weakness persists - maintain SELL. TRCL: Tepid quarter, high capex overhang retain SELL. Metals & Mining: Ferrous read-across: Steel recovery in CY24 - ArcelorMittal
Prabhudas Lilladhar increased Accumulate price target of Divi's Laboratories Ltd. to 6800.0 on 19 May, 2025.
More from Divi's Laboratories Ltd.
Recommended